Schubert & CO Incyte Corp Transaction History

Schubert & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	BUY	$70.23 - $86.01 $351 - $430	5 Added 9.62%	57 $4,000
Q4 2022 Jan 31, 2023	SELL	$67.18 - $84.11 $67 - $84	-1 Reduced 1.89%	52 $4,000
Q3 2022 Oct 21, 2022	SELL	$66.18 - $82.86 $926 - $1,160	-14 Reduced 20.9%	53 $4,000
Q2 2022 Aug 01, 2022	BUY	$66.18 - $83.18 $3,639 - $4,574	55 Added 458.33%	67 $5,000
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $264 - $318	4 Added 50.0%	12 $1,000
Q4 2021 Jan 28, 2022	BUY	$63.34 - $74.11 $506 - $592	8 New	8 $1,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

Stay updated on Schubert & CO with notifications on news.